Brimonidine Tartrate

Introduction Overview

Generic Name

brimonidine tartrate

Brand Name

Alphagan P

Dosage Form

ophthalmic solution

Drug Class

ophthalmic glaucoma agents

Pharmacokinetics

Absorption

Following ocular administration of brimonidine tartrate ophthalmic solution 0.2%, systemic absorption occurs with plasma concentrations peaking within 1 to 4 hours post-dose. The ocular route allows localized delivery to ocular tissues with relatively low systemic exposure. The systemic half-life of brimonidine is approximately 3 hours, reflecting rapid systemic clearance after absorption. Absorption may be influenced by factors such as ocular surface integrity, tear film dynamics, and nasolacrimal drainage potentially affecting systemic exposure levels.

Distribution

The protein binding characteristics of brimonidine in plasma have not been extensively studied; however, animal data and clinical pharmacology suggest moderate tissue distribution after systemic absorption. As a relatively lipophilic imidazoline derivative, brimonidine is able to penetrate ocular tissues to exert its effects on intraocular pressure. There is evidence from animal studies that brimonidine crosses the placenta and is excreted in breast milk, indicating some systemic tissue distribution beyond the eye.

Metabolism

Brimonidine undergoes extensive hepatic metabolism in humans following systemic absorption. Metabolic pathways are thought to involve oxidative and conjugative processes typical of imidazoline compounds, resulting in multiple metabolites which are pharmacologically inactive. These metabolic processes contribute to the rapid systemic clearance and short half-life observed after ocular dosing.

Elimination

The primary route of elimination of brimonidine and its metabolites is renal excretion. Approximately 87% of an orally administered radioactive dose was recovered within 120 hours, with 74% found in the urine, indicating efficient renal clearance. The pharmacokinetics in patients with renal or hepatic impairment have not been well characterized; hence caution is advised in these populations. Dialysis effects on brimonidine clearance are unknown.

Dosage Forms

Adults

For adult patients with open-angle glaucoma or ocular hypertension, the recommended dosage is one drop of brimonidine tartrate ophthalmic solution 0.2% instilled into the affected eye(s) three times daily, approximately eight hours apart. The solution may be used concomitantly with other topical ophthalmic agents, with a minimum 5-minute interval between different drops to prevent washout and ensure optimal absorption and effect.

Adolescents

The safety and effectiveness of brimonidine in pediatric patients aged 2 years and older have been evaluated, with caution advised due to observed side effects such as somnolence. The same dosing regimen of one drop three times daily is typically adopted, with careful monitoring for adverse effects, especially in younger children (ages 2–7 years). Dosing below age 2 years is contraindicated.

Special Populations

Brimonidine is contraindicated in neonates and infants under 2 years due to severe adverse effects including respiratory depression and somnolence. In geriatric patients, no significant differences in pharmacokinetics or safety have been observed, so standard adult dosing is applicable. In patients with hepatic or renal impairment, pharmacokinetics have not been studied; caution and close monitoring are recommended. Additionally, patients with severe cardiovascular disease require careful assessment prior to brimonidine use due to potential hypotensive effects.

Mechanism Of Action

Brimonidine tartrate is a relatively selective alpha-2 adrenergic receptor agonist that lowers intraocular pressure (IOP) through a dual mechanism. Primarily, it reduces aqueous humor production by binding to presynaptic alpha-2 receptors located on the ciliary epithelium, inhibiting adenylate cyclase and decreasing cyclic AMP levels, which reduces aqueous humor secretion. Secondly, brimonidine increases uveoscleral outflow, facilitating the drainage of aqueous humor via alternative pathways, thereby lowering IOP.

These pharmacodynamic actions result in a reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, and the peak hypotensive effect occurs approximately two hours after dosing. The selective alpha-2 agonist activity distinguishes brimonidine from other adrenergic agents, minimizing beta-adrenergic receptor mediated side effects.

At the cellular level, brimonidine’s binding to G protein-coupled alpha-2 receptors leads to reduced intracellular cAMP and modulation of ion channels influencing aqueous humor dynamics. In addition, alpha-2 receptor activation may exert neuroprotective effects on retinal ganglion cells, although this remains under investigation. The clinical implications of this dual effect make brimonidine a valuable therapeutic option to reduce IOP and potentially slow glaucomatous optic nerve damage.

Comparatively, brimonidine differs from beta-blockers (e.g., timolol) that lower IOP mainly by decreasing aqueous production without increasing outflow. Research supports that brimonidine’s unique mechanism may confer advantages in tolerability and efficacy, with studies demonstrating comparable IOP reduction to timolol when dosed appropriately.

Pharmacological Actions

Selective alpha-2 adrenergic receptor agonist activity.
Reduction of aqueous humor production in the ciliary body.
Enhancement of uveoscleral outflow of aqueous humor.
Topical ocular hypotensive agent lowering intraocular pressure.
Minimal systemic cardiovascular and pulmonary effects relative to non-selective agents.
Potential neuroprotective effects on retinal ganglion cells (under research).
Rapid onset of ocular hypotensive activity, peak at approximately 2 hours post-dose.
Dual mechanism provides additive IOP lowering effect compared with agents targeting only one pathway.
Decrease in ocular blood flow is minimal, preserving optic nerve perfusion.
Interaction with other topical ophthalmic hypotensives allows combined therapy.
Low systemic absorption reduces systemic side effects.
Presence of benzalkonium chloride preserves solution and maintains sterility.

Therapeutic Clinical Uses

Treatment of elevated intraocular pressure in open-angle glaucoma.
Management of ocular hypertension to prevent glaucoma progression.
Adjunctive therapy in patients inadequately responding to other topical glaucoma agents.
Lowering IOP in patients intolerant or contraindicated for beta-blockers.
Use in adults and children aged 2 years and older (with caution).
Off-label investigation for potential neuroprotective effects in ocular disease.
Used in combination therapy to enhance aqueous humor outflow and reduce production.
Preservation of visual field in progressive glaucoma with elevated IOP.

Side Or Adverse Effects

Oral dryness (10–30% incidence).
Ocular hyperemia (redness).
Burning and stinging sensation upon instillation.
Headache and blurred vision.
Foreign body sensation in the eye.
Fatigue and drowsiness, particularly in pediatric patients.
Conjunctival follicles and ocular allergic reactions.
Ocular pruritus (itching).
Corneal staining or erosion (3–9%).
Photophobia, eyelid erythema, and ocular discomfort.
Upper respiratory symptoms such as nasal dryness.
Dizziness and blepharitis.
Gastrointestinal symptoms and asthenia.
Depression, hypertension, anxiety (rare).
Postmarketing reactions include bradycardia, conjunctivitis, hypotension, iritis, conjunctival hemorrhage, and skin reactions such as rash and eyelid pruritus.

Precautions

Use with caution in patients with depression or cerebral/coronary insufficiency.
Monitor patients with Raynaud’s phenomenon, orthostatic hypotension, or thromboangiitis obliterans closely.
Caution in patients with severe cardiovascular disease.
Avoid contamination of the ophthalmic solution to prevent bacterial keratitis.
Advise patients to remove contact lenses prior to administration and wait at least 15 minutes before reinsertion due to benzalkonium chloride preservative.
Patients taking multiple ophthalmic drugs should wait at least 5 minutes between administrations.
Use caution when combined with systemic antihypertensives or cardiac glycosides due to potential additive hypotensive effects.
Monitor mental alertness in patients, especially those engaging in hazardous activities, due to possible somnolence or fatigue.
Careful consideration advised in pediatric use aged 2–7 years due to somnolence risk.
Avoid use in neonates and infants under 2 years due to severe systemic adverse reactions.
Observe for hypersensitivity reactions and discontinue if they occur.

Warnings

Potentiation of syndromes associated with vascular insufficiency.
Risk of severe cardiovascular effects in patients with serious cardiovascular disease.
Reports of bacterial keratitis due to contamination of multi-dose topical ophthalmic containers.
Possible severe respiratory and CNS depression in neonates and infants under 2 years.
Use cautiously with CNS depressants to avoid additive sedative effects.
Potential for decreased mental alertness; monitor patients accordingly.
Patients with ocular surgery or trauma should consult healthcare provider regarding continued use.
Preservative benzalkonium chloride may be absorbed by contact lenses and cause irritation.

Contraindications

Neonates and infants under the age of 2 years due to risk of severe systemic adverse effects.
Known hypersensitivity to brimonidine tartrate or any components of the formulation.
Previous hypersensitivity reactions to any ingredient in the ophthalmic solution.

Drug Interactions

Concomitant use with systemic antihypertensives or cardiac glycosides may potentiate hypotensive effects.
Use with central nervous system depressants (e.g., alcohol, barbiturates, opiates, sedatives) may increase sedation or drowsiness.
Tricyclic antidepressants may blunt the intraocular pressure lowering effect of brimonidine.
Monoamine oxidase inhibitors may increase the risk of systemic hypotension and other side effects due to altered metabolism.
Potential interactions with other topical ophthalmic agents require spacing doses by at least 5 minutes to avoid washout.

Preparations Of The Drug

Brimonidine tartrate ophthalmic solution 0.2% (2 mg/mL) sterile aqueous solution.
Available in multi-dose bottles of 5 mL, 10 mL, and 15 mL volumes with dropper tips.
Preserved with benzalkonium chloride 0.005% as a preservative.
Opaque white LDPE plastic bottles with purple HDPE caps.
Supplied as a clear, greenish-yellow solution with pH adjusted to 5.9 to 6.5.
NDC codes: 42571-419-92 (5 mL), 42571-419-56 (10 mL), and 42571-419-57 (15 mL).